Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Multiple factors are associated with a large variability in voriconazole exposure following
standard dose administration, such as non-linear saturable pharmacokinetics, drug-drug
interactions, liver disease, patient age, and genetic polymorphism of the metabolic enzymes.
Voriconazole is extensively metabolized by the human hepatic enzymes, primarily mediated by
CYP2C19. The polymorphisms account for a relatively large portion of inter-individual
variance observed in voriconazole plasma concentrations.
However, there are limited data on the relationships between voriconazole blood levels and
clinical outcomes or safety in Asian populations.
The purpose of this study is to investigate the relationships of voriconazole blood levels
with genetic polymorphism, safety, and clinical outcomes in immunocompromised patients with
invasive pulmonary aspergillosis.